ESC: Mavacamten Cuts Need for Septal Reduction Tx with Hypertrophic Cardiomyopathy

TUESDAY, Aug. 29, 2023 -- In patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), mavacamten reduces the need for septal reduction therapy (SRT) at week 56, according to a study published online Aug. 28 in JAMA Cardiology to...